Drugs Made In America Acquisition II Corp. $DMII Stake Lessened by Commonwealth of Pennsylvania Public School Empls Retrmt SYS

Commonwealth of Pennsylvania Public School Empls Retrmt SYS cut its stake in Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) by 12.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 350,000 shares of the company’s stock after selling 50,000 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Drugs Made In America Acquisition II were worth $3,490,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in DMII. Geode Capital Management LLC bought a new stake in shares of Drugs Made In America Acquisition II in the 4th quarter worth about $265,000. Virtu Financial LLC bought a new position in shares of Drugs Made In America Acquisition II during the fourth quarter worth about $317,000. ABC Arbitrage SA bought a new position in shares of Drugs Made In America Acquisition II during the fourth quarter worth about $396,000. Deltec Asset Management LLC acquired a new position in Drugs Made In America Acquisition II in the fourth quarter worth about $495,000. Finally, Royal Bank of Canada bought a new stake in Drugs Made In America Acquisition II in the fourth quarter valued at about $655,000.

Analyst Upgrades and Downgrades

DMII has been the topic of several research reports. Wall Street Zen upgraded Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. Weiss Ratings upgraded Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Drugs Made In America Acquisition II Stock Down 0.2%

Shares of DMII opened at $10.08 on Thursday. Drugs Made In America Acquisition II Corp. has a 12 month low of $9.86 and a 12 month high of $10.11. The stock’s fifty day moving average is $10.07.

Drugs Made In America Acquisition II Profile

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.